Trial Profile
Pharmacogenetic Study in Castration-resistant Prostate Cancer Patients Treated With Abiraterone Acetate
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary)
- Indications Prostate cancer
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms ABIGENE
- 03 Dec 2020 Status changed from active, no longer recruiting to completed.
- 10 Feb 2018 Results (n=109) presented at the 2018 Genitourinary Cancers Symposium
- 26 Jan 2018 Planned End Date changed from 1 Jun 2021 to 1 Dec 2020.